* Biogen - ‍new data reaffirm clinically meaningful benefit of Spinraza (nusinersen) in individuals with spinal muscular atrophy across disease severity​

* Biogen Inc - ‍Spinraza demonstrated motor function improvements in infants on permanent ventilation

* Biogen Inc - ‍No increase in risk of adverse events in children with Scoliosis​ Source text for Eikon: Further company coverage: